LSP Project 1-1
Immobilization of biocatalysts for the production of antibody derivatives for industrial application
Antibody derivatives have become an important aid, particularly in the treatment of cancer. However, efficient manufacturing methods for the economic production of stable and functional antibody derivatives on an industrial scale are still rare. Currently, all clinically used therapeutics of this type are being produced the classical chemical way. Consequences are an impairment of the functionality and stability, as well as negative impact on manufacturing costs. With the help of a self-developed enzyme-based approach, we aim for a more efficient production and for improved efficacy and quality of the antibody-based therapeutics. An efficient immobilization system is key for the economic efficiency of the entire production technology. The synthetic yield should be at least comparable and ideally even higher than under analogous conditions using the soluble enzyme. So far, the use of immobilized enzymes has been published and is applied in industry only for simple hydrolysis reactions (one-substrate reactions) or acyltransfer reactions between exclusively small molecules. The immobilization approach to be developed in the current project would be the first to allow the production of selectively modified antibodies based on the use of immobilized biocatalysts. The first part of the project will be followed by a pilot phase based on the results obtained, in which the initial laboratory scale is to be scaled up to industrially relevant product quantities. In this context, the immobilization must be performed at an appropriate scale, and the synthesis reaction must be adapted to the requirements of the larger scale regarding mass transfer, temperature, mixing, etc.
Staff
Prof. Dr. Frank Bordusa, Projektleiter
frank.bordusa@biochemtech.uni-halle.de
Tel: 0345 55 24800/ -01
Cooperating companies
IDT Biologika
BTI BioPharma